SOCS3 and myeloproliferative disorder: We found that the suppressor of cytokine signaling 3 (SOCS3) expression was significantly elevated in MPN patients with a JAK2 V617F mutation, suggesting that SOCS3 mRNA in peripheral blood can be used as a biomarker for diagnosis and assessment of MPN patients.